Fact Sheet
Pharma Sponsor Enlists Cenduit IRT to Rescue a Multi-Country, Multi-site Oncology Study
Achieves seamless transition to Cenduit IRT Mid-Study execution, while maintaining study timelines
Jul 16, 2021
Download
The sponsor assessed the safety and tolerability of escalating oral doses of one drug, when combined with the standard dosing of another, in patients with advanced solid malignancies. The client : a global pharmaceutical group focused on developing prescription drugs that target unmet medical needs in numerous indications including oncology.

Related solutions

Contact Us